NXI Therapeutics
Basel
About NXI Therapeutics
NXI Therapeutics specializes in the development of innovative immunosuppressive drugs aimed at treating autoimmune diseases and facilitating organ transplantation. The company focuses on creating drugs that offer high efficacy in managing these conditions. With a team led by CEO Ruben Herrendorff, who has extensive experience in preclinical and early clinical drug research and development, particularly in autoimmune and neuromuscular diseases, NXI Therapeutics is at the forefront of addressing complex medical challenges. The company operates within the biotechnology industry and is committed to advancing the field through its research initiatives.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: Less than $1M
- Total funding: $4.0M
- Funding stage: Seed
- Last round: Grant (Jun 2024)
- Website: nxitherapeutics.com
- Phone: +41 612077110
Industries & Categories
Biotechnology, Life Science, Medical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/nxi-therapeutics-41234 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.